The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,860.00
Bid: 1,860.00
Ask: 1,872.00
Change: 0.00 (0.00%)
Spread: 12.00 (0.645%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,860.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chief Executive Officer Retirement

23 Feb 2023 07:00

RNS Number : 7632Q
Genus PLC
23 February 2023
 

For Immediate Release 23 February 2023

 

Genus plc('Genus', or the 'Company')

Chief Executive Officer Retirement

 

Genus plc (LSE: GNS), a leading global animal genetics company, announces that Stephen Wilson, Chief Executive, has informed the Board of his intention to retire after ten years with the Company, the last four of which as Chief Executive Officer. Stephen has committed to remain with Genus until 30 September 2023 in order to achieve a smooth transition to a successor, while continuing to drive business strategy and performance.

A formal search for Stephen's successor has been initiated with an executive search agency and a further announcement will be made in due course.

On behalf of the Board, Iain Ferguson, the Chairman of Genus commented;

"During Stephen's time at Genus, including six years as Chief Financial Officer and four years as Chief Executive, the Company has made great strategic progress as a world-leading animal genetics company, making great strides in its vision to sustainably pioneer animal genetic improvement to help nourish the world.

"Stephen has overseen significant investment in the Group to support its long term strategic growth. These contributions have included the global launch of Sexcel, the significant strengthening of the Group's Research and Development capabilities, the ongoing PRRSv development programme, driving the Company's digital transformation, energising the Company's sustainability focus, broadening our geographic focus including growth in India and China, and investing in best in class animal facilities around the world. Stephen will leave the Company in excellent shape with a world-class leadership team, world-class genetics, and a growing innovation platform to enable the company to pursue many exciting future opportunities. Stephen has provided the Company with many years of strong leadership, and the Board and I remain excited by the Company's prospects. On behalf of the Board and all at Genus, I would like to thank Stephen for his commitment to the Company and his significant contributions to its success."

Stephen Wilson added "It has been a great privilege to lead such a talented group of people and develop a leading global agricultural biotechnology business with sustainability at the very heart of its development activities. After four years as Chief Executive and ten years as an executive director, I believe now is the right time for me to move to the next phase of my life. Genus has many strong growth opportunities, and I will remain fully focused on the continued successful execution of our strategy while the Board progresses the search for my successor."

Genus

Tel: +44(0)1256 345970

Iain Ferguson, ChairAlison Henriksen, Chief Financial Officer

Buchanan

Tel: +44(0)207 466 5000

Charles Ryland / Chris Lane / Verity Parker

This announcement is available on the Genus website www.genusplc.com

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Regulatory Notes

Details of Stephen Wilson's terms of departure are still to be finalised. Any such terms will be consistent with the Company's approved Directors Remuneration Policy. Details of any payments to be made to Stephen will be posted on the Company's website, in accordance with section 430(2B) Companies Act 2006. 

 

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014. The person responsible for making this announcement on behalf of the Group is Dan Hartley (General Counsel and Company Secretary).

 

This announcement is made in accordance with Listing Rule 9.6.11R. There are no matters to be disclosed in connection with Listing Rule 9.6.13R (2) - (6).

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAXAAALEDEFA
Date   Source Headline
2nd Jun 20177:00 amRNSTotal Voting Rights
1st Jun 20177:05 amRNSUpdate Regarding The Milk Pension Fund
2nd May 20173:00 pmRNSTotal Voting Rights
12th Apr 20174:48 pmRNSDirector/PDMR Shareholding
3rd Apr 20172:00 pmRNSTotal Voting Rights
3rd Apr 20177:00 amRNSSUCCESSFUL LEGAL OUTCOME FOR GENUS
15th Mar 20175:15 pmRNSDirector/PDMR Shareholding
15th Mar 201712:00 pmRNSDirector Declaration
1st Mar 201710:09 amRNSDirector/PDMR Shareholding
23rd Feb 20174:20 pmRNSCorrection of Record Date
23rd Feb 20177:00 amRNSInterim Results
23rd Feb 20177:00 amRNSAcquisition and strategic partnership
7th Feb 20174:00 pmRNSHolding(s) in Company
1st Feb 20172:00 pmRNSBlock listing Interim Review
13th Dec 20163:39 pmRNSDirector/PDMR Shareholding
1st Dec 20162:00 pmRNSTotal Voting Rights
17th Nov 20162:01 pmRNSResult of AGM
17th Nov 20167:00 amRNSAGM - Trading Update
1st Nov 20164:00 pmRNSTotal Voting Rights
31st Oct 20163:47 pmRNSAnnual Report and Annual General Meeting
26th Oct 20164:00 pmRNSHolding(s) in Company
11th Oct 20164:08 pmRNSDirector/PDMR Shareholding
3rd Oct 20166:09 pmRNSBlock Listing and Additional Listing
3rd Oct 20165:57 pmRNSTotal Voting Rights
29th Sep 20165:00 pmRNSDirector/PDMR Shareholding
15th Sep 20165:00 pmRNSDirector/PDMR Shareholding
8th Sep 20165:18 pmRNSDirector/PDMR Shareholding
8th Sep 20167:00 amRNSPreliminary Results
7th Sep 20167:00 amRNSNON-EXECUTIVE DIRECTOR RETIREMENT
1st Sep 20164:17 pmRNSTotal Voting Rights
15th Aug 20167:00 amRNSFINAL JURY DECISIONS IN US LITIGATION
12th Aug 20167:00 amRNSFURTHER DECISIONS IN US LITIGATION
11th Aug 20167:00 amRNSFIRST DECISIONS IN US ANTI-TRUST LITIGATION
1st Aug 20169:20 amRNSBlock listing Interim Review
1st Aug 20169:09 amRNSTotal Voting Rights
27th Jul 20167:00 amRNSSigns exclusive licence for tech. to combat BRD
15th Jul 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
1st Jul 20163:10 pmRNSTotal Voting Rights
17th Jun 20164:40 pmRNSSecond Price Monitoring Extn
17th Jun 20164:35 pmRNSPrice Monitoring Extension
1st Jun 20162:00 pmRNSTotal Voting Rights
18th May 20167:00 amRNSExclusive Licence for Leading Gene Editing Tech
3rd May 20162:29 pmRNSTotal Voting Rights
13th Apr 20163:13 pmRNSDirector/PDMR Shareholding
1st Apr 20163:31 pmRNSDirector/PDMR Shareholding
9th Mar 20165:03 pmRNSDirector/PDMR Shareholding
4th Mar 20169:30 amRNSBOARD APPOINTMENT
3rd Mar 20162:00 pmRNSDirector/PDMR Shareholding
1st Mar 20165:17 pmRNSDirector/PDMR Shareholding
23rd Feb 20167:00 amRNSINTERIM RESULTS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.